SMAC Mimetics: a new class of targeted agents that activate apoptotic cell death and block pro-survival signalling in cancer cells By Dr Mark A. McKinlay SMAC mimetics are a new class of targeted drugs being developed for the treatment of solid tumours and hematologic cancers. SMAC mimetics specifically induce apoptotic… Read More
By Dr Aaron Heifetz The promise of stem cell technology as a tool for drug discovery, drug development and as a therapeutic modality is no longer in the future but part of contemporary healthcare. The speed which stem cells have been integrated into biomedical product development has surprised many, but… Read More
Epigenetics: Targeting the mediator between environment and phenotype By Dr John M. Rosenfeld, Dr Kan Saito and Dr Michael Sturges Although it is still early days in terms of our understanding of epigenetics, the fast development of new tools and technologies to define genome-wide epigenetic variations in humans has the… Read More
DNA Diagnostics Gets Digitised - Quantitative real-time PCR By Dr Mikael Kubista and Dr Anders Stahlberg Quantitative real-time PCR (qPCR) has during the last two decades emerged as the preferred technology for nucleic acid analysis in routine as well as in research. qPCR has the sensitivity to detect a single… Read More
Targeting Target Cancer Metabolism - What is fuelling the resurgence? By Dr Neil P. Jones Targeting the metabolic pathways of cancer is a hot topic for drug discovery. The central dogma is that cancers have a higher demand for metabolic inputs to aid proliferation and survival and that this could… Read More
By Dr Lesley J Millatt, Dr Rmy Hanf and Dr Dean W Hum According to the International Diabetes Federation, more than 285 million people (6.4% of the world population) are currently estimated to suffer from diabetes, a figure which is expected to rise to 438 million (7.8%) by 2030. Moreover,… Read More
Utilising Biomarkers to Eliminate Drug Candidates with Cardiotoxicity in Preclinical Development By Dr Federica Crivellente The rapidly escalating costs of drug development is causing the biopharmaceutical industry to focus its R&D efforts on identifying new technologies and methods that can predict the safety and efficacy of new compounds as early… Read More
Early Patient Stratification is Critical to Enable Effective and Personalised Drug Discovery and Development By Dr David A Fryburg, Dr Diane H Song and Dr David de Graaf With the current chances of an efficacious outcome in Phase II for novel mechanisms being in the region of 1 in 5,… Read More
In Vivo Preclinical Imaging - An Essential Tool in Translational Research By Dr John Comley In vivo imaging of small animals (mainly mice) is increasingly being deployed across the drug development process, particularly in the oncology/cancer therapeutic area. One of the main applications is monitoring the treatment response for early… Read More
In Vivo Cell Reprogramming: Current status and potential clinical applications By Dr Shili Wu, Jonathan Pang, Bobby Baravati, Jun Bao and Dr Yong Zhu In Vivo Cell Reprogramming, or IVR, is a new technology that can be used to develop cures for incurable diseases. Using a combination of protein, small… Read More
3D Cell Culture Developments to Improve In Vitro Analyses By Prof Stefan Przyborski Improved in vitro models are required to aid the identification and assessment of candidate molecules for pharmaceutical development. Conventional cell culture models involve the growth of cells on two-dimensional (2D) substrates. Cells adapt to this synthetic 2D… Read More
Enabling the Promise of Stem Cells By Robert Shaw and Dr Jeff Till The remarkable potential of stem cells to generate several hundred differentiated cell types is driving their use for regenerative medicine and for supporting the traditional drug discovery and development process (Figure 1). However, sustained progress in these… Read More
The Post Genomic Era: What Does It All Mean? By Dr Chris Torrance Information may no longer be a bottleneck to understanding and tackling complex genetic diseases such as cancer. For those who cut their research teeth not so very long ago, before PCR was thought of by Kary Mullis,… Read More
Epigenetics: An Emerging Target Class for Drug Screening By Dr John Comley Heightened awareness of the potential importance of epigenetic targets in many disease areas, and growing vendor interest in developing new assays to screen DNA methylation and histone modifications encouraged HTStec to undertake market research in this area in… Read More
Protein Biomarker Immunoassays: Opportunities and Challenges By Dr M. Walid Qoronfleh and Dr Klaus Lindpaintner With the biopharma industry under heavy pressure, transforming the scientific interchange between the laboratory and the clinic is exceedingly critical. Realising the costly toll of drug attrition in late-stage development, many companies are turning to… Read More
Induced Pluripotent Stem Cells: A model for transforming drug discovery By Dr Dwight Morrow and Dr Julie Holder Induced pluripotent stem (iPS) cells have the potential to transform drug discovery by providing physiologically relevant cells for toxic compound identification, target validation, compound screening, and tool discovery. The technology for generating… Read More